GO:0090101 negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090101 describes any process that decreases the rate, frequency, or extent of signaling initiated by a transmembrane receptor serine/threonine kinase after ligand binding.
• This term covers negative regulation of TGF-beta, BMP, activin, and related receptor pathways, which are central to development, tissue homeostasis, and disease.
• Key negative regulators include inhibitory Smads (SMAD6, SMAD7), E3 ubiquitin ligases (SMURF1, SMURF2), and phosphatases that target receptor complexes.
• Dysregulation of these negative feedback mechanisms contributes to cancer, fibrosis, and skeletal disorders, making them attractive therapeutic targets.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect causal roles of negative regulators in this pathway.
• Understanding GO:0090101 helps researchers design experiments that test how cells terminate or dampen TGF-beta superfamily signaling.
Description
The Gene Ontology term GO:0090101, negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway, defines any process that decreases the rate, frequency, or extent of signaling triggered when a transmembrane receptor serine/threonine kinase binds its physiological ligand. This term is critical because transmembrane receptor serine/threonine kinases, such as TGF-beta, BMP, and activin receptors, control diverse cellular decisions including proliferation, differentiation, apoptosis, and extracellular matrix production. Without negative regulation, these pathways can become hyperactive, leading to pathological conditions such as cancer, fibrosis, and developmental defects. Researchers studying this term aim to identify the molecular brakes that keep receptor signaling in check and to understand how these brakes fail in disease. The negative regulation can occur at multiple levels, including ligand sequestration, receptor degradation, inhibitory Smad competition, and phosphatase-mediated inactivation of receptor complexes. Because the pathway is highly conserved and clinically relevant, GO:0090101 serves as a unifying annotation for diverse negative feedback mechanisms that fine-tune TGF-beta superfamily signaling.
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway At A Glance
| GO ID | GO:0090101 |
|---|---|
| GO term | negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway |
| Ontology | biological_process |
| Synonym | negative regulation of transmembrane receptor protein serine/threonine kinase signalling pathway |
| Major function | Dampening or terminating signaling downstream of TGF-beta, BMP, activin, and related receptor serine/threonine kinases |
| Key negative regulators | SMAD6, SMAD7, SMURF1, SMURF2, FKBP12, PP1, PP2A |
| Associated diseases | Cancer, fibrosis, skeletal disorders, and developmental anomalies |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, proteomics |
What Is GO:0090101?
In my own words, GO:0090101 refers to any biological process that reduces the strength, duration, or frequency of signals generated when a transmembrane receptor serine/threonine kinase binds its natural ligand. This includes mechanisms that block receptor activation, promote receptor degradation, inhibit downstream Smad proteins, or activate phosphatases that turn off the receptor. The term is a child of negative regulation of signaling and is specific to receptors that have intrinsic serine/threonine kinase activity, such as TGF-beta, BMP, and activin receptors.
Why Is negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway Important in Cell Biology?
GO:0090101 is important because transmembrane receptor serine/threonine kinase signaling is a central hub for growth, differentiation, and immune regulation, and its negative regulation prevents excessive or prolonged signaling that can drive disease. For example, loss of inhibitory Smad7 or Smurf ubiquitin ligases leads to enhanced TGF-beta signaling, which promotes fibrosis and tumor progression. Conversely, excessive negative regulation can contribute to impaired tissue repair and developmental defects. Therefore, understanding this term helps researchers identify therapeutic targets and design experiments to modulate pathway activity with precision.
• Prevents uncontrolled TGF-beta superfamily signaling that can cause fibrosis and cancer.
• Maintains tissue homeostasis by balancing growth-promoting and growth-inhibitory signals.
• Influences immune cell development and function, including marginal zone B cell regulation.
• Controls bone metabolism and skeletal development through BMP and activin pathways.
• Provides targets for drugs that aim to enhance or inhibit receptor signaling in disease.
• Helps explain resistance to TGF-beta-targeted therapies in oncology.
• Is essential for proper embryonic patterning and organogenesis.
• Links to autophagy and metabolic regulation in bone and other tissues.
What Happens During negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway?
Ligand sequestration and decoy receptors
In simple terms: The cell can mop up the signal before it reaches the receptor.
Negative regulation can begin extracellularly, where soluble decoy receptors or binding proteins sequester ligands such as TGF-beta, BMPs, or activins, preventing them from engaging transmembrane serine/threonine kinase receptors. This reduces the effective concentration of active ligand and dampens downstream Smad activation. For example, noggin and gremlin bind BMPs and inhibit BMP receptor signaling, a mechanism critical in development and bone formation. Similarly, follistatin sequesters activin, thereby negatively regulating activin receptor signaling.
Inhibitory Smads (I-Smads) SMAD6 and SMAD7
In simple terms: Inside the cell, inhibitory Smads block the pathway by interfering with receptor-Smad interactions.
SMAD6 and SMAD7 are the principal intracellular negative regulators of TGF-beta superfamily signaling. SMAD7 binds to activated type I receptors and prevents the phosphorylation of receptor-regulated Smads (R-Smads), thereby blocking signal propagation. SMAD6 preferentially inhibits BMP signaling by competing with SMAD1/5/8 for type I receptor binding and by recruiting E3 ligases to the receptor complex. Both I-Smads are transcriptionally induced by TGF-beta/BMP signaling, forming a negative feedback loop that limits the duration and intensity of the response.
Ubiquitination and degradation of receptors
In simple terms: Tagging receptors for destruction is a major way to shut down signaling.
E3 ubiquitin ligases such as SMURF1 and SMURF2 promote the ubiquitination and proteasomal degradation of activated type I receptors and SMAD proteins. SMURF2, in complex with SMAD7, targets the TGF-beta receptor complex for degradation, thereby terminating signaling. Other E3 ligases, including NEDD4-2 and WWP1, also regulate receptor stability and downstream Smad turnover. This degradation machinery is essential for preventing sustained signaling that could otherwise drive fibrosis or oncogenesis.
Phosphatases and kinase inactivation
In simple terms: Enzymes called phosphatases remove phosphate groups to turn off the receptor.
Protein phosphatases such as PP1 and PP2A can dephosphorylate activated type I receptors and R-Smads, reversing the phosphorylation events required for signal transduction. For instance, PP1 associates with the TGF-beta receptor complex and dephosphorylates TbetaRI, reducing its kinase activity. Additionally, the immunophilin FKBP12 binds to and stabilizes the inactive conformation of type I receptors, preventing ligand-independent activation. These mechanisms provide rapid, reversible negative regulation of receptor serine/threonine kinase signaling.
Transcriptional feedback and cross-talk
In simple terms: The pathway can turn on its own brakes by increasing the expression of negative regulators.
Activation of TGF-beta/BMP signaling induces the expression of negative regulators such as SMAD7, SMURF2, and SKI/SKIL, which then feedback to inhibit the pathway. This transcriptional feedback ensures that signaling is self-limiting. Cross-talk with other pathways, such as the MAPK or PI3K pathways, can also modulate the strength of receptor serine/threonine kinase signaling by affecting the stability or activity of Smads and receptors. Such integration is crucial for context-dependent cellular responses.
Key Genes Involved in GO:0090101 negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
The following genes encode key components and negative regulators of transmembrane receptor serine/threonine kinase signaling, with well-documented roles in the literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SMAD7 | Inhibitory Smad that blocks type I receptor-mediated R-Smad phosphorylation | Frequently studied as a negative feedback regulator in TGF-beta signaling; knockout models show enhanced fibrosis |
| SMAD6 | Inhibitory Smad that preferentially inhibits BMP signaling | Key for BMP-related skeletal and developmental studies; knockout leads to cardiovascular defects |
| SMURF1 | E3 ubiquitin ligase targeting BMP receptor and Smads for degradation | Regulates BMP signaling in bone and cancer; knockout affects bone mass |
| SMURF2 | E3 ubiquitin ligase that degrades TGF-beta receptors and SMAD proteins | Critical for terminating TGF-beta signaling; knockout causes embryonic lethality |
| FKBP12 | Immunophilin that stabilizes inactive type I receptors and prevents ligand-independent activation | Used to study receptor autoinhibition; knockout leads to BMP-like phenotypes |
| SKI | Transcriptional co-repressor that inhibits Smad-mediated transcription | Oncogenic role in melanoma and other cancers; knockout enhances TGF-beta responses |
| SKIL (SnoN) | Transcriptional co-repressor that negatively regulates TGF-beta signaling | Involved in cancer and fibrosis; knockout affects epithelial-mesenchymal transition |
| PPP1CA | Catalytic subunit of PP1 that dephosphorylates type I receptors | Studied for receptor inactivation; overexpression reduces TGF-beta signaling |
| PPP2CA | Catalytic subunit of PP2A that dephosphorylates Smads and receptors | Tumor suppressor context; knockout increases Smad phosphorylation |
| TGFBR1 | Type I receptor for TGF-beta; target of negative regulation | Mutated in cancer; used to study feedback inhibition |
| TGFBR2 | Type II receptor for TGF-beta; target of negative regulation | Frequently mutated in cancer; knockout models show loss of negative feedback |
| BMPR1A | Type I receptor for BMP; regulated by SMAD6 and SMURF1 | Mutations cause juvenile polyposis; knockout affects bone and development |
| BMPR2 | Type II receptor for BMP; regulated by inhibitory Smads | Mutations linked to pulmonary arterial hypertension; knockout models available |
| ACVR1 | Type I receptor for activin; negatively regulated by FKBP12 and SMAD7 | Mutations cause fibrodysplasia ossificans progressiva; knockout models exist |
| ACVR2A | Type II receptor for activin; target of negative regulation | Studied in reproduction and cancer; knockout affects gonadal function |
| NEDD4L | E3 ubiquitin ligase that ubiquitinates TGF-beta receptors | Regulates receptor turnover; knockout affects signaling duration |
| WWP1 | E3 ubiquitin ligase that targets Smads for degradation | Oncogenic role in breast cancer; knockout reduces tumor growth |
| TGFB1 | Ligand for TGF-beta receptor; its signaling is negatively regulated | Knockout causes multi-organ inflammation; used to study feedback |
How Is negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway Regulated?
The negative regulation of transmembrane receptor serine/threonine kinase signaling is itself tightly regulated. For example, the expression of SMAD7 and SMURF2 is induced by TGF-beta/BMP signaling, creating a negative feedback loop that limits the duration of the response. Post-translational modifications, such as phosphorylation and ubiquitination, control the stability and activity of inhibitory Smads and E3 ligases. Additionally, cross-talk with other signaling pathways, including MAPK and PI3K/AKT, can modulate the effectiveness of negative regulators. Autophagy has also been implicated in regulating bone metabolism and may influence TGF-beta family signaling components. The immunophilin FKBP12 provides a constitutive brake by maintaining receptors in an inactive state until ligand binding.
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SMAD7 | Fibrosis, cancer | Knockout and overexpression in fibroblasts and cancer cell lines |
| SMURF2 | Cancer, fibrosis | Knockout in mouse models and human cell lines |
| ACVR1 | Fibrodysplasia ossificans progressiva | Point mutation knock-in in mice and patient-derived iPSCs |
| BMPR2 | Pulmonary arterial hypertension | Knockout and point mutation in endothelial cells |
| TGFBR2 | Cancer, Marfan syndrome | Knockout and point mutation in epithelial and fibroblast cells |
Cancer
Dysregulation of negative regulators in the TGF-beta pathway is common in cancer. Loss of SMAD7 or SMURF2 can lead to enhanced TGF-beta signaling, which promotes epithelial-mesenchymal transition, invasion, and metastasis. Conversely, some cancers overexpress SMAD7, which can paradoxically enhance oncogenesis by blocking growth-inhibitory TGF-beta responses. E3 ubiquitin ligases such as WWP1 are amplified in breast and prostate cancers and contribute to tumor progression by degrading tumor-suppressive Smads. Therefore, components of GO:0090101 are considered potential therapeutic targets in oncology.
Fibrosis and tissue remodeling
Excessive TGF-beta signaling drives fibrosis in organs such as lung, liver, and kidney. Negative regulators like SMAD7 and SMURF2 normally keep this in check, but their downregulation or inactivation leads to sustained receptor activity and increased extracellular matrix deposition. In animal models, overexpression of SMAD7 attenuates fibrosis, highlighting the therapeutic potential of enhancing negative regulation. Similarly, BMP signaling negative regulators influence bone and cartilage homeostasis, and their dysregulation contributes to skeletal disorders.
Skeletal and developmental disorders
BMP and activin signaling are critical for bone and cartilage development, and their negative regulation by SMAD6, SMURF1, and FKBP12 is essential for proper skeletal formation. Mutations in BMPR1A or BMPR2 that impair negative feedback can cause juvenile polyposis or pulmonary arterial hypertension. In fibrodysplasia ossificans progressiva, mutations in ACVR1 disrupt FKBP12-mediated inhibition, leading to constitutive activin-like signaling and heterotopic ossification. These examples underscore the clinical importance of GO:0090101 in developmental and skeletal diseases.
Immune and hematopoietic regulation
TGF-beta superfamily signaling is a key regulator of immune cell development and function. Negative regulation of this pathway is important for preventing excessive immunosuppression or autoimmunity. For instance, TACI (TNFRSF13B) regulates marginal zone B cell development, and its function intersects with TGF-beta family signaling. Autophagy, which can be modulated by TGF-beta signaling, also influences bone metabolism and immune cell survival. Thus, GO:0090101 has implications for immune-related disorders and hematological malignancies.
From negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SMAD7 enhance TGF-beta signaling? | SMAD7 knockout cell line (e.g., HEK293 or fibroblasts) |
| Does a specific point mutation in ACVR1 disrupt FKBP12 binding? | ACVR1 point mutation knock-in (e.g., R206H) in iPSCs or mice |
| Can overexpression of SMURF2 reduce fibrosis? | SMURF2 overexpression in hepatic stellate cells or mouse models |
| What is the effect of SMAD6 knockout on BMP signaling? | SMAD6 knockout in osteoblasts or chondrocytes |
| How does tagged SMAD7 localize after TGF-beta stimulation? | Knock-in of fluorescent tag (e.g., GFP) at SMAD7 locus |
| Does CRISPR activation of SMAD7 protect against fibrosis? | CRISPRa overexpression of SMAD7 in vivo |
How to Study the negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Assess negative regulator requirement in pathway |
| Point mutation knock-in | Specific amino acid change | Test domain function or disease mutation |
| Tagged knock-in | Protein localization and dynamics | Image negative regulator recruitment |
| Overexpression | Gain of function | Test suppression of signaling |
| RNA-seq | Transcriptome changes | Identify downstream targets of negative regulation |
| Phosphoproteomics | Phosphorylation status | Measure Smad and receptor kinase activity |
| Co-immunoprecipitation | Protein-protein interactions | Detect SMAD7-receptor or SMURF2-SMAD complexes |
| Luciferase reporter assay | Pathway activity | Quantify TGF-beta/BMP signaling in live cells |
CRISPR knockout and point mutation
CRISPR-Cas9 knockout is widely used to delete negative regulators such as SMAD7, SMURF2, or FKBP12 to assess their role in dampening receptor signaling. Point mutations can be introduced to disrupt specific domains, such as the SMAD7 inhibitory domain or the FKBP12 binding site on ACVR1, to test their functional impact. These models help establish causality between negative regulator loss and pathway hyperactivation.
Knock-in and tagged reporters
Knock-in of epitope tags (e.g., HA, FLAG) or fluorescent proteins (e.g., GFP) at endogenous loci allows real-time tracking of negative regulator localization, stability, and interactions. For example, tagging SMAD7 enables imaging of its recruitment to the receptor complex after TGF-beta stimulation. Knock-in of luciferase reporters downstream of Smad-binding elements can quantify pathway activity in live cells.
Overexpression and rescue experiments
Overexpression of negative regulators such as SMAD7 or SMURF2 is used to test whether enhancing their levels can suppress TGF-beta/BMP signaling and related phenotypes. Rescue experiments in knockout backgrounds can confirm specificity. For instance, re-expressing SMAD7 in SMAD7-knockout cells restores negative regulation. These approaches are valuable for validating therapeutic strategies.
Transcriptomics and proteomics
RNA-seq and quantitative proteomics can identify global changes in gene expression and protein abundance upon manipulation of negative regulators. Phosphoproteomics is particularly useful to measure changes in Smad phosphorylation and receptor kinase activity. These methods provide systems-level insights into how GO:0090101 modulates cellular networks.
How CRISPR Can Be Used to Study GO:0090101 negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
Knockout
CRISPR knockout of negative regulators such as SMAD7, SMURF2, or FKBP12 leads to enhanced and prolonged receptor serine/threonine kinase signaling, providing direct evidence for their inhibitory role. These models are used to study fibrosis, cancer, and developmental defects. For example, SMAD7 knockout mice exhibit increased TGF-beta signaling and aggravated tissue fibrosis.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to disrupt specific functional domains. For instance, the ACVR1 R206H mutation, which impairs FKBP12-mediated inhibition, is a classic example of a point mutation that dysregulates negative regulation and causes fibrodysplasia ossificans progressiva. Such models help dissect molecular mechanisms and test targeted therapies.
Knock-in
Knock-in of reporter tags or conditional alleles allows precise tracking and temporal control of negative regulators. Tagged SMAD7 knock-in enables visualization of its nuclear-cytoplasmic shuttling and receptor interaction. Conditional knock-in of mutant receptors can model disease onset in specific tissues.
Overexpression
CRISPR activation (CRISPRa) or traditional overexpression vectors can increase levels of negative regulators to test whether boosting their activity suppresses pathological signaling. Overexpression of SMAD7 or SMURF2 has been shown to attenuate TGF-beta-induced fibrosis and tumor progression in preclinical models. These gain-of-function models are essential for validating therapeutic targets.
How EDITGENE Supports negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway Research
Researchers studying negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway-related genes often need to determine whether a candidate gene is causally involved in dampening or terminating receptor signaling. This requires precise genetic models that can knockout, mutate, tag, or overexpress the gene of interest in relevant cell types. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such studies, from single-gene editing to high-throughput library screening and bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway research.
Frequently Asked Questions About negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
What is GO:0090101?
GO:0090101 is a Gene Ontology term for any process that decreases the rate, frequency, or extent of signaling initiated by a transmembrane receptor serine/threonine kinase after ligand binding.
What genes are involved in negative regulation of TGF-beta signaling?
Key genes include SMAD7, SMAD6, SMURF1, SMURF2, FKBP12, SKI, SKIL, and phosphatases such as PP1 and PP2A.
How does SMAD7 inhibit TGF-beta signaling?
SMAD7 binds to activated type I receptors and prevents R-Smad phosphorylation, and it also recruits E3 ligases to degrade the receptor complex.
What diseases are linked to defective negative regulation of BMP signaling?
Defective negative regulation can cause pulmonary arterial hypertension, juvenile polyposis, and fibrodysplasia ossificans progressiva.
What experimental models are used to study GO:0090101?
CRISPR knockout, point mutation knock-in, tagged knock-in, overexpression, and CRISPR library screening are commonly used.
How does SMURF2 regulate TGF-beta receptor levels?
SMURF2 is an E3 ubiquitin ligase that ubiquitinates TGF-beta receptors and Smads, targeting them for proteasomal degradation.
Can overexpression of SMAD7 reduce fibrosis?
Yes, preclinical studies show that increasing SMAD7 levels can attenuate TGF-beta-induced fibrosis in various tissues.
What is the role of FKBP12 in receptor serine/threonine kinase signaling?
FKBP12 binds to type I receptors and stabilizes their inactive conformation, preventing ligand-independent activation.
How can CRISPR screening identify new negative regulators?
Genome-wide knockout or activation screens can reveal genes whose loss or gain alters TGF-beta/BMP signaling, uncovering novel components of GO:0090101.
Why is negative regulation of activin signaling important?
Activin signaling controls reproduction, development, and cancer; its negative regulation by follistatin and inhibitory Smads prevents excessive signaling.
Conclusion
GO:0090101, negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway, is a fundamental biological process that keeps TGF-beta, BMP, and activin signaling in check. The literature highlights a diverse array of negative regulators, including inhibitory Smads, E3 ubiquitin ligases, phosphatases, and decoy receptors, that act at multiple levels to fine-tune signaling duration and intensity. Dysregulation of these mechanisms contributes to cancer, fibrosis, skeletal disorders, and immune dysfunction, making them important therapeutic targets. Advances in CRISPR-based models and high-throughput screening will continue to uncover new components and therapeutic opportunities within this pathway.
References
- 1. Wang J et al.. 2023. The role of autophagy in bone metabolism and clinical significance.. Autophagy 19(9):2409-2427 PMID: 36858962
- 3. Itoh S et al.. 2007. Negative regulation of TGF-beta receptor/Smad signal transduction.. Curr Opin Cell Biol 19(2):176-84 PMID: 17317136
- 5. Gomez-Puerto MC et al.. 2019. Bone morphogenetic protein receptor signal transduction in human disease.. J Pathol 247(1):9-20 PMID: 30246251
- 6. Sinha A et al.. 2021. E3 Ubiquitin Ligases: Key Regulators of TGFβ Signaling in Cancer Progression.. Int J Mol Sci 22(2) PMID: 33418880
- 7. Luff DH et al.. 2026. TACI regulates marginal zone B cell development.. J Exp Med 223(6) PMID: 42085021
- 8. Choi SC et al.. 2011. Negative regulation of activin signal transduction.. Vitam Horm 85:79-104 PMID: 21353877
